No option-patients : Is angiogenesis with gene or cell therapy still an option?
|
|
- Louise Parks
- 5 years ago
- Views:
Transcription
1 No option-patients : Is angiogenesis with gene or cell therapy still an option? Professor Sigrid Nikol Clinical and Interventional Angiology Asklepios-Klinik St. Georg Hamburg, Germany
2 Angiogenic gene therapy trials: randomized placebo-controlled phase II TRIAL Disease targeted Growth factor Route of delivery Pt. # included Result RAVE PAD claudication VEGF 121 intramuscular 105 negative for peak walking distance WALK PAD claudication Hif-1a intramuscular 287 negative for peak walking distance DELTA-1 PAD claudication Del-1 intramuscular 105 negative for peak walking distance VEGF PVD PAD CLI VEGF 165 local catheter-mediated 54 positive for angiogr. increase of collaterals Groningen trial PAD CLI VEGF 165 intramuscular 54 positive for hemodynamics TALISMAN 201 PAD CLI FGF-1 intramuscular 125 positive for amputation HGF-STAT PAD CLI HGF intramuscular 104 positive for TcPO2 HGF-CLI PAD CLI HGF intramuscular 40 Postive for rest pain and ulcer size
3 Primary outcome event rate (%) Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E; Lancet. 377(9781): , 2011 TAMARIS Primary Endpoint Time to Major Amputation or Death NV1FGF 30 Placebo Placebo N=259 NV1FGF N=266 Hazard ratio (95% CI) P 5 Major amputation or death 86 (33.20%) 96 (37.07%) 1.11 (0.83, 1.49) 0.48 Number at Risk Months since randomization Placebo NV1FGF
4 Cell therapy any better?
5 Effect via growth factors released by human endothelial progenitor cells Human EPCs were transplanted into immunocompromised nude mice, and the levels of cytokines were measured by both human- and mouse-specific primers and probes. Cho HJ J Exp Med. 204: , 2007
6 Clinical trials for PAD: Bone marrow-derived cells Study level: 1a, double-blind; 1b, randomised, non-blinded controlled trial; 2, controlled trial; 3, cohort study/historical controls; 4. patient series/uncontrolled trial Lawall H et al, Thromb Haemost 2010; 103:
7 Clinical trials in PAD: Mobilised mononuclear blood cells Study level: 1a, double-blind; 1b, randomised, non-blinded controlled trial; 2, controlled trial; 3, cohort study/historical controls; 4. patient series/uncontrolled trial Lawall H et al, Thromb Haemost 2010; 103:
8 Powell et al. J Vasc Surg 2011 Autologous bone marow cells RESTORE CLI 1st prospective, randomized double-blind, placebo-controlled multicenter trial 79 pt. Time to first occurence of therapy failure: combined endpoint for major amputation, doubeling of ulcer size, occurence of new gamgrene or death positive Amputation-free survival
9 Teraa M et al, Circulation Jan 7. [Epub ahead of print] Effect of Repetitive Intra-Arterial Infusion of Bone Marrow Mononuclear Cells in Patients With No-Option Limb Ischemia: The Randomized, Double-Blind, Placebo-Controlled JUVENTAS Trial. negative 160 patients with severe, non-revascularizable limb ischemia to prevent major amputation Repetitive (3x; 3-weeks interval) intra-arterial infusion of BMMNC or placebo. Primary endpoint major amputation at 6 months: - 19% in the BMMNC vs. 13% in the placebo group (Relative risk [RR] 1.46; 95% confidence interval [CI] 0.62 to 3.42), not significantly different Safety endpoints at 6 months: - all-cause mortality, occurrence of malignancy or hospitalization due to infection) not significantly different between the groups (RR 1.46; 95%CI 0.63 to 3.38) - all-cause mortality at six months with 5% vs. 6% (RR 0.78; 95%CI 0.22 to 2.80). Secondary outcomes: - quality of life, rest pain, ankle-brachial index, and transcutaneous oxygen pressure improved during follow-up with no significant differences between the groups.
10 Forest plot with 95% CIs pain (after 4-8 weeks, 12 weeks, 24 weeks and 48 weeks) in the RCT group (A) and the non-rct group (B) Wang Z-X J Atheroscler Thromb, 2014; 21:1183
11 Forest plot with 95% CIs pain (after 4-8 weeks, 12 weeks, 24 weeks and 48 weeks) in the RCT group (A) and the non-rct group (B) Wang Z-X J Atheroscler Thromb, 2014; 21:1183
12 Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials Teraa M et al. Ann Surg Dec;258(6):922 Meta-analysis of all randomized controlled trials (RCTs) - BM-derived cell therapy compared to standard care with or without placebo - in CLI patients - Major amputation and amputation-free survival were considered as the primary endpoints - 12 RCTs jointly including 510 CLI patients When only the placebo-controlled RCTs were considered, major amputations rates were considerably reduced and nonsignificant (RR = 0.78; 95% CI, ; P = 0.46). Amputation-free survival did not significantly differ between the BM treated and the control group (RR = 1.16; 95% CI, ; P = 0.22). CONCLUSIONS: Results of placebo-controlled and non-placebo-controlled RCTs seem to diverge, which stresses the necessity to use placebo in the control arms of these trials as well as long-term follow-up data to assess durability of treatment effects.
13 With inceasing cardiovascular risk less progenitor cells are available! The number of EPCs correlates inversely with the Framingham risk score of each individual patient Hill JM et al. N Engl J Med, 348: , 2003
14 Lower circulating progenitor cell levels in CLI patients Teraa M et al. PLoS One. 2013; 8(1): e55592
15 Teraa M et al. irc Res. 2014;114:311 Critical limb ischemia (CLI) is associated with decreased microvascular density Microscopic photographs of -human bone marrow from control (A), -CLI-diabetes mellitus (DM)+ (B), -and CLI-DM (C) donors, stained for microvascular marker CD34. A distinction was made between microvessels (MVs) and nonvessel structures, most likely hematopoietic stem cells (HSCs).
16 EPC levels and mobilization in diabetes Diminished mobilization response in diabetes Westerweel PE et al. PLoS One. 2013;8(3):e60357
17 Other sources of allogenic cells possible??
18 PLX- Placenta-derived stem cells for Peripheral Artery Disease
19 The PLX Manufacturing Platform Placenta Adherent stromal cells (ASCs) at the 2D growth phase Carrier Bioreactor 19
20 Angiogenesis PLX Secrete Angiogenic Factors VEGF (pg/ml) PLX PLX + TGFb PD B03 PD270611AS1 PD B04 P150811R01 P060711R02 PLX-1 PLX-2 PLX-3 PLX-4 PLX-5 186B02 VEGF is secreted by PLX TGF beta stimulates VEGF secretion in PLX
21 Angiogenesis Tube Formation EGM (positive control) EBM2 EBM2 +PLX CM PLX conditioned media induce tube formation in endothelial cells
22 Drug Delivery Platform PLX cells are administered Intramuscularly Ongoing randomized trial in claudicants Randomized trial in CLI being prepared
23 Other Options? Yes! - Neuronal stem cells - Mesenchymal stem cells - Genetically modified cells - Induced stem cells - Germline stem cells -...
24 Thank-you
Financial Disclosures. Bone Marrow Mononuclear Cells. Cell Based Therapies: What Do They Do and Will They Work in CLI?
Cell Based Therapies: What Do They Do and Will They Work in CLI? None Financial Disclosures Michael P. Murphy, MD The Vascular and Cardiac Adult Stem Cell Therapy Center Indiana University School of Medicine
More informationCell Therapy for Peripheral Arterial Disease
Medical Policy Manual Medicine, Policy No. 141 Cell Therapy for Peripheral Arterial Disease Next Review: October 2018 Last Review: October 2017 Effective: December 1, 2017 IMPORTANT REMINDER Medical Policies
More informationPopulations Interventions Comparators Outcomes Individuals: With peripheral arterial disease
Protocol Stem Cell Therapy for Peripheral Arterial Disease (80155) Medical Benefit Effective Date: 10/01/11 Next Review Date: 07/18 Preauthorization No Review Dates: 07/11, 07/12, 07/13, 07/14, 07/15,
More informationCorporate Medical Policy
Corporate Medical Policy Stem-cell Therapy for Peripheral Arterial Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: stem_cell_therapy_for_peripheral_arterial_disease 7/2011
More informationStem-cell Therapy for Peripheral Arterial Disease
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMEDICAL POLICY POLICY TITLE STEM-CELL THERAPY FOR PERIPHERAL ARTERIAL DISEASE POLICY NUMBER MP-2.089
Original Issue Date (Created): April 24, 2012 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Treatment of peripheral arterial disease, including critical
More informationTopic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, Section: Medicine Last Reviewed Date: October 2013
Medical Policy Manual Topic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No: 141 Effective Date: January
More informationStem-Cell Therapy for Peripheral Arterial Disease. Description
Page: 1 of 12 Last Review Status/Date: September 2015 Description Critical limb ischemia due to peripheral arterial disease (PAD) results in pain at rest, ulcers, and significant risk for limb loss. Injection
More informationResults of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease
Am J Cardiovasc Drugs (2017) 17:235 242 DOI 10.1007/s40256-016-0210-3 ORIGINAL RESEARCH ARTICLE Results of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients
More informationPeripheral Artery Disease Compendium. Modulating the Vascular Response to Limb Ischemia. Angiogenic and Cell Therapies
Peripheral Artery Disease Compendium Circulation Research Compendium on Peripheral Artery Disease Epidemiology of Peripheral Artery Disease Pathogenesis of the Limb Manifestations and Exercise Limitations
More informationNorbert Weiss (1), Sigrid Nikol (2), Yael Rosen (3), Dan Peres (3), Zami Aberman (3), Manesh R Patel (4), for the PLX-PAD Study Group
A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo- Controlled, Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX- PAD Cells
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationAutologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results
ARTIcle Autologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results Min Li, 1 Hua Zhou, 2 Xing Jin, 2 Mo Wang, 2 Shiyi Zhang, 2 Lei Xu 2 Abstract
More informationResults of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication
786926TAK0010.1177/1753944718786926Therapeutic Advances in Cardiovascular DiseaseR Deev, I Plaksa research-article2018 Therapeutic Advances in Cardiovascular Disease Original Research Results of 5-year
More informationFrom the Society for Vascular Surgery
From the Society for Vascular Surgery Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity
More informationDeWitt Daughtry Family Department of Surgery Division of Vascular Surgery University of Miami
31 st Annual Florida Vascular Society Scientific Session Orlando, FL April 26 th, 2018 Intramuscular E-selectin/AAV Gene Therapy Promotes Wound Healing in a Critical Limb Ischemia Mouse Model Punam P.
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationCell-Based Therapies for Peripheral Arterial Disease
Journal of Stem Cell Research & Therapy ISSN: 2157-7633 Journal of Stem Cell Research & Therapy Fujita and Kawamoto, 2014, 4:9 DOI: 10.4172/2157- Review Article Cell-Based Therapies for Peripheral Arterial
More informationTreatment of Diabetic Foot Ulcers and Peripheral Artery Disease with Placenta-Derived Adherent Cells
Treatment of Diabetic Foot Ulcers and Peripheral Artery Disease with Placenta-Derived Adherent Cells Steven Fischkoff, MD Celgene Cellular Therapeutics Warren, NJ, USA Celgene Cellular Therapeutics Placental
More informationDiagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
More informationVascular screening in diabetic patients: how aggressive should we be and when to intervene?
Vascular screening in diabetic patients: how aggressive should we be and when to intervene? Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy Disclosure Speaker name: ROBERTO FERRARESI X X
More information2 Powell et al. patients with CLI in patients without revascularization options. Interim safety and efficacy analyses are reported.
Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical
More informationUse of Adipose-Derived Stem Cells in Regenerative Therapy. David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas
Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus,
More informationStem Cell Therapy Concept. Pleuripotent Stromal Cells 8/8/2011. Use of Adipose-Derived Stem Cells in Regenerative Therapy
Use of Adipose-Derived Stem Cells in Regenerative Therapy Use of Adipose-Derived Stem Cells in Regenerative Therapy David Euhus, MD Professor of Surgery UT Southwestern Medical Center at Dallas David Euhus,
More informationCurrent developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free?
Published 17 December 2010, doi:10.4414/smw.2010.13130 Cite this as: Current developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free? Zijiang Yang a, Stefano
More informationFemoropopliteal Above-Knee Bypass: The True Results
Femoropopliteal Above-Knee Bypass: The True Results Lise Pyndt Jørgensen, Camilla Rasmussen & Torben V Schroeder Rigshospitalet and University of Copenhagen, DENMARK Treatment options in the femoropopliteal
More informationDisclosures. Objectives. Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach. Christopher D. Owens, MD 4/23/2009
Disclosures Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach No disclosures No conflicts of interest Christopher D. Owens, MD Objectives Changing face of our patients presenting
More informationClinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
More informationUtility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis
2016 Annals of Vascular Diseases doi:10.3400/avd.oa.16-00074 Original Article Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis Kazuo Tsuyuki, CVT, PhD, 1 Kenji Kohno, PhD,
More informationCOMPANY PRESENTATION July 2018
COMPANY PRESENTATION July 2018 Forward looking Statement This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S.
More informationMesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future
Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future Cell Therapy 2014 Las Vegas, NV, USA Sulaiman Al-Hashmi, PhD Sultan Qaboos University Oman What are MSCs? Stem
More informationProfessor Harvey White. Interventional Cardiologist Auckland
Professor Harvey White Interventional Cardiologist Auckland Stem cells and the heart Harvey White Director of Coronary Care Unit and Cardiovascular Research Unit Green Lane Cardiovascular Service Auckland
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationNational Clinical Conference 2018 Baltimore, MD
National Clinical Conference 2018 Baltimore, MD No relevant financial relationships to disclose Wound Care Referral The patient has been maximized from a vascular standpoint. She has no other options.
More informationMy Diabetic Patient Has No Pulses; What Should I Do?
Emily Malgor, MD Assistant Professor of Surgery University of Oklahoma, Oklahoma City My Diabetic Patient Has No Pulses; What Should I Do? There are no disclosures. Background Diabetes affects 387 million
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationUC SF. Disclosures. Vascular Assessment of the Diabetic Foot. What are the best predictors of wound healing? None. Non-Invasive Vascular Studies
Disclosures Vascular Assessment of the Diabetic Foot What are the best predictors of wound healing? None Shant Vartanian MD Assistant Professor of Vascular Surgery UCSF Vascular Symposium April 20, 2013
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationStem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford
Stem Cells Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford Adult Stem Cells Unique cells that are capable of self-renewal Have the ability to differentiate
More informationDisclosures. Critical Limb Ischemia. Vascular Testing in the CLI Patient. Vascular Testing in Critical Limb Ischemia UCSF Vascular Symposium
Disclosures Vascular Testing in the CLI Patient None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of Vascular Surgery Critical Limb Ischemia Chronic Limb
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationIMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
More informationMultidisciplinary approach to BTK Y. Gouëffic, MD, PhD
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD Department of vascular surgery, University Hospital of Nantes, France Response to the increased demand of hospital care Population is aging Diabetes
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationJohn E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationJAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE
JAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd Beaufort SC 29907 Copyright Pending 2017 All rights reserved, including the
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationThe clinical consequences of peripheral arterial disease
Clinical and Population Studies Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease Hirofumi Makino, Motokuni Aoki,
More informationVenous interventions in venous treatment and recurrence avoidance an overview
Venous interventions in venous treatment and recurrence avoidance an overview Professor Alun H Davies Section of Vascular Surgery Charing Cross & St Mary s Hospitals London Introduction Common, distressing
More informationHistory & Literature Review
History & Literature Review History In the earliest stages of research, ACI Medical observed significant increases in arterial blood flow while testing a device that applied rapid, high level compressions
More informationArterial Studies And The Diabetic Foot Patient
Arterial Studies And The Patient George L. Berdejo, BA, RVT, FSVU gberdejo@wphospital.org Disclosures I have nothing to disclose! Diabetes mellitus continues to grow in global prevalence and to consume
More informationProspects of Adult Stem cells therapy in Peripheral Vascular Diseases
BJMP 2010;3(4):a345 Review Article Prospects of Adult Stem cells therapy in Peripheral Vascular Diseases Jayprakash Gopall, Wen Huang and Yu Zhao ABSTRACT Peripheral Vascular Disease (PVD) is a growing
More informationMesenchymal Stem Cells
Mesenchymal Stem Cells Science and therapeutic applications Dirk Büscher (Former VP-R&D Cellerix) GRIFOLS SA May 10 th, 2010 EMA 1 Discovery and Definition of Mesenchymal Stem Cells MSC must be plastic-adherent
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More informationObjective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationIncreased blood flow. natural healing response. generates a. Wound Healing. Providing increased blood circulation to promote wound healing from inside
Increased blood flow generates a natural healing response Wound Healing Providing increased blood circulation to promote wound healing from inside Increased blood circulation generates a natural healing
More informationPractical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
More informationCELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK: CISS Phase I Trial
CELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK: CISS Phase I Trial Lauralyn McIntyre, MD, FRCPC, MHSc Associate Professor, University of Ottawa Senior Scientist, Ottawa Hospital Research Institute CCCF MEETING,
More informationHIGH- VOLTAGE PULSED CURRENT (HVPC) ELECTRICAL STIMULATION FOR TREATMENT OF DIABETIC FOOT ULCER (DFU) - A REVIEW
Review Article Allied Science International Journal of Pharma and Bio Sciences ISSN 0975-6299 HIGH- VOLTAGE PULSED CURRENT (HVPC) ELECTRICAL STIMULATION FOR TREATMENT OF DIABETIC FOOT ULCER (DFU) - A REVIEW
More informationInternational Journal of Pharma and Bio Sciences
Research Article Nursing International Journal of Pharma and Bio Sciences ISSN 0975-6299 EFFECTIVENESS OF ALLEN BUERGER EXERCISE IN PREVENTING PERIPHERAL ARTERIAL DISEASE AMONG PEOPLE WITH TYPE II DIABETES
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationIntra-arterial Allogeneic Mesenchymal Stem Cells for Critical Limb Ischemia are Safe and Efficacious: Report of a Phase I Study
World J Surg (2013) 37:915 922 DOI 10.1007/s00268-012-1892-6 Intra-arterial Allogeneic Mesenchymal Stem Cells for Critical Limb Ischemia are Safe and Efficacious: Report of a Phase I Study Anjan Kumar
More informationParacrine Mechanisms in Adult Stem Cell Signaling and Therapy
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy Massimiliano Gnecchi, Zhiping Zhang, Aiguo Ni, Victor J. Dzau Circulation Research 2008 Nov 21;103(11):1204-19 Introduction(1) After AMI all
More informationDiminished Circulating Monocytes after Peripheral Bypass Surgery for Critical Limb Ischemia
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 5-6-2009 Diminished Circulating Monocytes after Peripheral Bypass
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationWIEF-AFF ROUNDTABLE Tokyo, Japan 26 May 2015
WIEF-AFF ROUNDTABLE 2015 Tokyo, Japan 26 May 2015 Regenerative Medicine Goal: - To restore organ +/- tissue function - For pts with serious injuries or chronic disease where the body unable to heal & restore
More informationStrategic Research Development in Stem Cell and Regenerative Medicine in HKU Professor Sum-ping Lee Dean HKU Li Ka Shing Faculty of Medicine
Strategic Research Development in Stem Cell and Regenerative Medicine in HKU Professor Sum-ping Lee Dean HKU Li Ka Shing Faculty of Medicine Adult stem cells Cells that are capable of self renewal and
More informationMaking the difference with Live Image Guidance
Live Image Guidance 2D Perfusion Making the difference with Live Image Guidance In Peripheral Arterial Disease Real-time results, instant assessment Severe foot complications the result of hampered blood
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationOptimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial
Optimization of Generx (Ad5FGF-4) Clinical Trial Design for Refractory Angina: Interim Results of the Phase 3 ASPIRE Trial Gabor M Rubanyi, MD. PhD. Angionetics Inc., San Diego, CA ASGCT, New Orleans,
More informationInterventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
More informationIliac Crest: The Gold Standard
Iliac Crest: The Gold Standard Iliac crest is often considered the gold standard for harvesting. The iliac crest contains bone marrow which is a rich source of regenerative cells, including: Endothelial
More informationCarlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium
Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationReview Article Clinical Application of Vascular Regenerative Therapy for Peripheral Artery Disease
Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 179730, 6 pages http://dx.doi.org/10.1155/2013/179730 Review Article Clinical Application of Vascular Regenerative Therapy
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationSPINACH Making Limb Salvage Salad from Spinach alone
SPINACH Making Limb Salvage Salad from Spinach alone Surgical reconstruction versus Peripheral Intervention in patients with critical limb ischemia prospective multicenter registry in Japan Nobuyoshi Azuma,
More informationImproved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement
From the Society for Vascular Surgery Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement Eric Benoit, MD,
More informationAre DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
More informationSalvaging the Unsalvageable: Intermittent Pneumatic Compression and Foot Ulcer Healing. Revascularize (when possible)
Salvaging the Unsalvageable: Intermittent Pneumatic Compression and Foot Ulcer Healing Thom Rooke, MD Thom Krehbiel Professor of Vascular Medicine Mayo Clinic Approach to the Severely Ischemic Limb Identify
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationFor No-Option patients, there is now another option. Dr. Michael Lichtenberg, Klinikum Arsnberg, Germany
From No Hope to New Hope For No-Option patients, there is now another option. Dr. Michael Lichtenberg, Klinikum Arsnberg, Germany Our Unique Solution The LimFlow system leverages a scientifically proven
More informationPERIPHERAL ARTERIAL DISEASE (PAD); Frequency in diabetics.
PERIPHERAL ARTERIAL DISEASE (PAD); Frequency in diabetics. ORIGINAL PROF-2084 Dr. Qaiser Mahmood, Dr. Nasreen Siddique, Dr. Affan Qaiser ABSTRACT Objectives: (1) To determine the frequency of PAD in diabetic
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationQuality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationDr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK
Advanced heart failure - devices, mechanical circulatory support and cardiac transplantation Monday 30 January 2017 Stem cell and gene therapies for heart failure Dr. Alexander Lyon Senior Lecturer and
More informationKoen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationStem cell applications- Cord blood, Cord tissue, Fat tissue
Stem cell applications- Cord blood, Cord tissue, Fat tissue Annual General Meeting of Shareholders 18 May 2011 Arnoud van Tulder Chief Executive Officer 1 Latest news about stem cells (1/3) New heartwithownstem
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationJune 15 th, 2005 RAC Meeting
June 15 th, 2005 RAC Meeting Presentation Outline Introduction MGVS Overview Peripheral arterial disease (PAD) Angiogenesis, Therapeutic angiogenesis MultiGeneAngio Product MultiGeneAngio Preclinical studies:
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More information